Exact Mass: 611.3067316

Exact Mass Matches: 611.3067316

Found 63 metabolites which its exact mass value is equals to given mass value 611.3067316, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Lercanidipine

3-{1-[(3,3-diphenylpropyl)(methyl)amino]-2-methylpropan-2-yl} 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

C36H41N3O6 (611.2995206)


C - Cardiovascular system > C08 - Calcium channel blockers > C08C - Selective calcium channel blockers with mainly vascular effects > C08CA - Dihydropyridine derivatives C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker

   

Lercanidipine

3-{1-[(3,3-diphenylpropyl)(methyl)amino]-2-methylpropan-2-yl} 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

C36H41N3O6 (611.2995206)


Lercanidipine is only found in individuals that have used or taken this drug. It is a calcium channel blocker of the dihydropyridine class. It is sold under various commercial names including Zanidip.By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Lercanidipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload. C - Cardiovascular system > C08 - Calcium channel blockers > C08C - Selective calcium channel blockers with mainly vascular effects > C08CA - Dihydropyridine derivatives C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker

   

Dihydroergocristine

N-[7-benzyl-2-hydroxy-5,8-dioxo-4-(propan-2-yl)-3-oxa-6,9-diazatricyclo[7.3.0.0^{2,6}]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraene-4-carboxamide

C35H41N5O5 (611.3107536)


   

NSC409663

NSC409663

C35H41N5O5 (611.3107536)


   

Salannolactam 23|Salannolactam-(23)

Salannolactam 23|Salannolactam-(23)

C34H45NO9 (611.309416)


   

GE20372 B

GE20372 B

C30H41N7O7 (611.3067316)


   

C34H45NO9

C34H45NO9 (611.309416)


   

Salannolactam 21|Salannolactam-(21)

Salannolactam 21|Salannolactam-(21)

C34H45NO9 (611.309416)


   

dihydroergocristine

dihydroergocristine

C35H41N5O5 (611.3107536)


Ergocristine in which a single bond replaces the double bond between positions 9 and 10. It is used as the mesylate salt for the symptomatic treatment of mental deterioration associated with cerebrovascular insufficiency and in peripheral vascular disease. C - Cardiovascular system > C04 - Peripheral vasodilators > C04A - Peripheral vasodilators > C04AE - Ergot alkaloids C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents Origin: Microbe; SubCategory_DNP: Alkaloids derived from tryptophan, Ergot alkaloids, Clavine alkaloid relative retention time with respect to 9-anthracene Carboxylic Acid is 0.971 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.968 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.966 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.965

   

GE-20372-A/B

GE-20372-A/B

C30H41N7O7 (611.3067316)


   

Phe Phe Ile Trp

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-phenylpropanamido]-3-methylpentanamido]-3-(1H-indol-3-yl)propanoic acid

C35H41N5O5 (611.3107536)


   

Phe Phe Leu Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-phenylpropanamido]-4-methylpentanamido]-3-(1H-indol-3-yl)propanoic acid

C35H41N5O5 (611.3107536)


   

Phe Phe Trp Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-phenylpropanamido]-3-(1H-indol-3-yl)propanamido]-3-methylpentanoic acid

C35H41N5O5 (611.3107536)


   

Phe Phe Trp Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-phenylpropanamido]-3-(1H-indol-3-yl)propanamido]-4-methylpentanoic acid

C35H41N5O5 (611.3107536)


   

Phe Ile Phe Trp

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-methylpentanamido]-3-phenylpropanamido]-3-(1H-indol-3-yl)propanoic acid

C35H41N5O5 (611.3107536)


   

Phe Ile Trp Phe

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-methylpentanamido]-3-(1H-indol-3-yl)propanamido]-3-phenylpropanoic acid

C35H41N5O5 (611.3107536)


   

Phe Leu Phe Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-4-methylpentanamido]-3-phenylpropanamido]-3-(1H-indol-3-yl)propanoic acid

C35H41N5O5 (611.3107536)


   

Phe Leu Trp Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-4-methylpentanamido]-3-(1H-indol-3-yl)propanamido]-3-phenylpropanoic acid

C35H41N5O5 (611.3107536)


   

Phe Trp Phe Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-(1H-indol-3-yl)propanamido]-3-phenylpropanamido]-3-methylpentanoic acid

C35H41N5O5 (611.3107536)


   

Phe Trp Phe Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-(1H-indol-3-yl)propanamido]-3-phenylpropanamido]-4-methylpentanoic acid

C35H41N5O5 (611.3107536)


   

Phe Trp Ile Phe

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-(1H-indol-3-yl)propanamido]-3-methylpentanamido]-3-phenylpropanoic acid

C35H41N5O5 (611.3107536)


   

Phe Trp Leu Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-(1H-indol-3-yl)propanamido]-4-methylpentanamido]-3-phenylpropanoic acid

C35H41N5O5 (611.3107536)


   

Ile Phe Phe Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-phenylpropanamido]-3-phenylpropanamido]-3-(1H-indol-3-yl)propanoic acid

C35H41N5O5 (611.3107536)


   

Ile Phe Trp Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-phenylpropanamido]-3-(1H-indol-3-yl)propanamido]-3-phenylpropanoic acid

C35H41N5O5 (611.3107536)


   

Ile Trp Phe Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-(1H-indol-3-yl)propanamido]-3-phenylpropanamido]-3-phenylpropanoic acid

C35H41N5O5 (611.3107536)


   

Leu Phe Phe Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-phenylpropanamido]-3-phenylpropanamido]-3-(1H-indol-3-yl)propanoic acid

C35H41N5O5 (611.3107536)


   

Leu Phe Trp Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-phenylpropanamido]-3-(1H-indol-3-yl)propanamido]-3-phenylpropanoic acid

C35H41N5O5 (611.3107536)


   

Leu Trp Phe Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-(1H-indol-3-yl)propanamido]-3-phenylpropanamido]-3-phenylpropanoic acid

C35H41N5O5 (611.3107536)


   

Trp Phe Phe Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-phenylpropanamido]-3-phenylpropanamido]-3-methylpentanoic acid

C35H41N5O5 (611.3107536)


   

Trp Phe Phe Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-phenylpropanamido]-3-phenylpropanamido]-4-methylpentanoic acid

C35H41N5O5 (611.3107536)


   

Trp Phe Ile Phe

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-phenylpropanamido]-3-methylpentanamido]-3-phenylpropanoic acid

C35H41N5O5 (611.3107536)


   

Trp Phe Leu Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-phenylpropanamido]-4-methylpentanamido]-3-phenylpropanoic acid

C35H41N5O5 (611.3107536)


   

Trp Ile Phe Phe

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-methylpentanamido]-3-phenylpropanamido]-3-phenylpropanoic acid

C35H41N5O5 (611.3107536)


   

Trp Leu Phe Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-4-methylpentanamido]-3-phenylpropanamido]-3-phenylpropanoic acid

C35H41N5O5 (611.3107536)


   

PG-PS

1-hexadecanoyl-2-glutaryl-sn-glycero-3-phosphoserine

C27H50NO12P (611.307047)


   

Dihydroergocristine

N-[7-benzyl-2-hydroxy-5,8-dioxo-4-(propan-2-yl)-3-oxa-6,9-diazatricyclo[7.3.0.0^{2,6}]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraene-4-carboxamide

C35H41N5O5 (611.3107536)


relative retention time with respect to 9-anthracene Carboxylic Acid is 0.966 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.965 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.968 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.971

   

(6Ar,9R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide

(6Ar,9R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide

C35H41N5O5 (611.3107536)


   

N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide

N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide

C35H41N5O5 (611.3107536)


   

N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide

N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide

C35H41N5O5 (611.3107536)


   

N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide

N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide

C35H41N5O5 (611.3107536)


   

N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide

N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide

C35H41N5O5 (611.3107536)


   

N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide

N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide

C35H41N5O5 (611.3107536)


   

Ile-Phe-Phe-Trp

Ile-Phe-Phe-Trp

C35H41N5O5 (611.3107536)


   

2-[[5-(diaminomethylideneamino)-1-[[3-methyl-1-oxo-1-[[(2S)-1-oxo-3-phenylpropan-2-yl]amino]butan-2-yl]amino]-1-oxopentan-2-yl]carbamoylamino]-3-(4-hydroxyphenyl)propanoic acid

2-[[5-(diaminomethylideneamino)-1-[[3-methyl-1-oxo-1-[[(2S)-1-oxo-3-phenylpropan-2-yl]amino]butan-2-yl]amino]-1-oxopentan-2-yl]carbamoylamino]-3-(4-hydroxyphenyl)propanoic acid

C30H41N7O7 (611.3067316)


   

SHexCer 21:2;3O

SHexCer 21:2;3O

C27H49NO12S (611.2975314)


   

Nehydrin

Nehydrin

C35H41N5O5 (611.3107536)


   

LSM-1707

LSM-1707

C35H41N5O5 (611.3107536)


   

1-palmitoyl-2-glutaryl-sn-glycero-3-phosphoserine

1-palmitoyl-2-glutaryl-sn-glycero-3-phosphoserine

C27H50NO12P (611.307047)


   

LSM-1568

LSM-1568

C35H41N5O5 (611.3107536)


   

PS 16:0/5:1;O2

PS 16:0/5:1;O2

C27H50NO12P (611.307047)


   

ST 26:7;O4;HexNAc

ST 26:7;O4;HexNAc

C34H45NO9 (611.309416)


   

ST 29:4;O6;Tau

ST 29:4;O6;Tau

C31H49NO9S (611.3127864)


   

14-(acetyloxy)-6-(2-hydroxy-5h-pyrrol-3-yl)-10-(2-methoxy-2-oxoethyl)-7,9,11,15-tetramethyl-3,17-dioxapentacyclo[9.6.1.0²,⁹.0⁴,⁸.0¹⁵,¹⁸]octadec-7-en-12-yl 2-methylbut-2-enoate

14-(acetyloxy)-6-(2-hydroxy-5h-pyrrol-3-yl)-10-(2-methoxy-2-oxoethyl)-7,9,11,15-tetramethyl-3,17-dioxapentacyclo[9.6.1.0²,⁹.0⁴,⁸.0¹⁵,¹⁸]octadec-7-en-12-yl 2-methylbut-2-enoate

C34H45NO9 (611.309416)


   

(1r,2s,4r,6r,9r,10r,11r,12s,14r,15r,18r)-14-(acetyloxy)-6-(2-hydroxy-5h-pyrrol-3-yl)-10-(2-methoxy-2-oxoethyl)-7,9,11,15-tetramethyl-3,17-dioxapentacyclo[9.6.1.0²,⁹.0⁴,⁸.0¹⁵,¹⁸]octadec-7-en-12-yl (2e)-2-methylbut-2-enoate

(1r,2s,4r,6r,9r,10r,11r,12s,14r,15r,18r)-14-(acetyloxy)-6-(2-hydroxy-5h-pyrrol-3-yl)-10-(2-methoxy-2-oxoethyl)-7,9,11,15-tetramethyl-3,17-dioxapentacyclo[9.6.1.0²,⁹.0⁴,⁸.0¹⁵,¹⁸]octadec-7-en-12-yl (2e)-2-methylbut-2-enoate

C34H45NO9 (611.309416)


   

2-[({4-carbamimidamido-1-[(2-methyl-1-{[(2r)-1-oxo-3-phenylpropan-2-yl]-c-hydroxycarbonimidoyl}propyl)-c-hydroxycarbonimidoyl]butyl}-c-hydroxycarbonimidoyl)amino]-3-(4-hydroxyphenyl)propanoic acid

2-[({4-carbamimidamido-1-[(2-methyl-1-{[(2r)-1-oxo-3-phenylpropan-2-yl]-c-hydroxycarbonimidoyl}propyl)-c-hydroxycarbonimidoyl]butyl}-c-hydroxycarbonimidoyl)amino]-3-(4-hydroxyphenyl)propanoic acid

C30H41N7O7 (611.3067316)


   

(2s)-2-({[(1s)-4-carbamimidamido-1-{[(1s)-2-methyl-1-{[(2s)-1-oxo-3-phenylpropan-2-yl]-c-hydroxycarbonimidoyl}propyl]-c-hydroxycarbonimidoyl}butyl]-c-hydroxycarbonimidoyl}amino)-3-(4-hydroxyphenyl)propanoic acid

(2s)-2-({[(1s)-4-carbamimidamido-1-{[(1s)-2-methyl-1-{[(2s)-1-oxo-3-phenylpropan-2-yl]-c-hydroxycarbonimidoyl}propyl]-c-hydroxycarbonimidoyl}butyl]-c-hydroxycarbonimidoyl}amino)-3-(4-hydroxyphenyl)propanoic acid

C30H41N7O7 (611.3067316)


   

10-hydroxy-8-[3-hydroxy-4,8-dimethyl-9-(2-methyl-1,3-oxazol-4-yl)nona-4,6,8-trien-2-yl]-11,16-dimethyl-4,7,12,18-tetraoxatetracyclo[15.3.1.0³,⁵.0¹¹,¹³]henicos-14-ene-6,19-dione

10-hydroxy-8-[3-hydroxy-4,8-dimethyl-9-(2-methyl-1,3-oxazol-4-yl)nona-4,6,8-trien-2-yl]-11,16-dimethyl-4,7,12,18-tetraoxatetracyclo[15.3.1.0³,⁵.0¹¹,¹³]henicos-14-ene-6,19-dione

C34H45NO9 (611.309416)


   

14-(acetyloxy)-6-(5-hydroxy-2h-pyrrol-3-yl)-10-(2-methoxy-2-oxoethyl)-7,9,11,15-tetramethyl-3,17-dioxapentacyclo[9.6.1.0²,⁹.0⁴,⁸.0¹⁵,¹⁸]octadec-7-en-12-yl 2-methylbut-2-enoate

14-(acetyloxy)-6-(5-hydroxy-2h-pyrrol-3-yl)-10-(2-methoxy-2-oxoethyl)-7,9,11,15-tetramethyl-3,17-dioxapentacyclo[9.6.1.0²,⁹.0⁴,⁸.0¹⁵,¹⁸]octadec-7-en-12-yl 2-methylbut-2-enoate

C34H45NO9 (611.309416)


   

(1r,2s,4r,6r,9r,10r,11r,12s,14r,15r,18r)-14-(acetyloxy)-6-(5-hydroxy-2h-pyrrol-3-yl)-10-(2-methoxy-2-oxoethyl)-7,9,11,15-tetramethyl-3,17-dioxapentacyclo[9.6.1.0²,⁹.0⁴,⁸.0¹⁵,¹⁸]octadec-7-en-12-yl (2e)-2-methylbut-2-enoate

(1r,2s,4r,6r,9r,10r,11r,12s,14r,15r,18r)-14-(acetyloxy)-6-(5-hydroxy-2h-pyrrol-3-yl)-10-(2-methoxy-2-oxoethyl)-7,9,11,15-tetramethyl-3,17-dioxapentacyclo[9.6.1.0²,⁹.0⁴,⁸.0¹⁵,¹⁸]octadec-7-en-12-yl (2e)-2-methylbut-2-enoate

C34H45NO9 (611.309416)


   

(2s)-2-({[(1s)-4-carbamimidamido-1-{[(1s)-2-methyl-1-{[(2r)-1-oxo-3-phenylpropan-2-yl]-c-hydroxycarbonimidoyl}propyl]-c-hydroxycarbonimidoyl}butyl]-c-hydroxycarbonimidoyl}amino)-3-(4-hydroxyphenyl)propanoic acid

(2s)-2-({[(1s)-4-carbamimidamido-1-{[(1s)-2-methyl-1-{[(2r)-1-oxo-3-phenylpropan-2-yl]-c-hydroxycarbonimidoyl}propyl]-c-hydroxycarbonimidoyl}butyl]-c-hydroxycarbonimidoyl}amino)-3-(4-hydroxyphenyl)propanoic acid

C30H41N7O7 (611.3067316)


   

(1s,3s,5r,8s,10s,11r,13r,14e,16r,17r)-10-hydroxy-8-[(2r,3r,4e,6e,8e)-3-hydroxy-4,8-dimethyl-9-(2-methyl-1,3-oxazol-4-yl)nona-4,6,8-trien-2-yl]-11,16-dimethyl-4,7,12,18-tetraoxatetracyclo[15.3.1.0³,⁵.0¹¹,¹³]henicos-14-ene-6,19-dione

(1s,3s,5r,8s,10s,11r,13r,14e,16r,17r)-10-hydroxy-8-[(2r,3r,4e,6e,8e)-3-hydroxy-4,8-dimethyl-9-(2-methyl-1,3-oxazol-4-yl)nona-4,6,8-trien-2-yl]-11,16-dimethyl-4,7,12,18-tetraoxatetracyclo[15.3.1.0³,⁵.0¹¹,¹³]henicos-14-ene-6,19-dione

C34H45NO9 (611.309416)


   

2-[({4-carbamimidamido-1-[(2-methyl-1-{[(2s)-1-oxo-3-phenylpropan-2-yl]-c-hydroxycarbonimidoyl}propyl)-c-hydroxycarbonimidoyl]butyl}-c-hydroxycarbonimidoyl)amino]-3-(4-hydroxyphenyl)propanoic acid

2-[({4-carbamimidamido-1-[(2-methyl-1-{[(2s)-1-oxo-3-phenylpropan-2-yl]-c-hydroxycarbonimidoyl}propyl)-c-hydroxycarbonimidoyl]butyl}-c-hydroxycarbonimidoyl)amino]-3-(4-hydroxyphenyl)propanoic acid

C30H41N7O7 (611.3067316)


   

(14e)-10-hydroxy-8-[(4e,6e,8e)-3-hydroxy-4,8-dimethyl-9-(2-methyl-1,3-oxazol-4-yl)nona-4,6,8-trien-2-yl]-11,16-dimethyl-4,7,12,18-tetraoxatetracyclo[15.3.1.0³,⁵.0¹¹,¹³]henicos-14-ene-6,19-dione

(14e)-10-hydroxy-8-[(4e,6e,8e)-3-hydroxy-4,8-dimethyl-9-(2-methyl-1,3-oxazol-4-yl)nona-4,6,8-trien-2-yl]-11,16-dimethyl-4,7,12,18-tetraoxatetracyclo[15.3.1.0³,⁵.0¹¹,¹³]henicos-14-ene-6,19-dione

C34H45NO9 (611.309416)